Skip to content

The Effect of BiosLife on Serum Lipids

The Effect of an Integrative Dietary Supplement on the Lipid Profile of Subjects With Hypercholesterolemia

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00457756
Enrollment
100
Registered
2007-04-06
Start date
2007-01-31
Completion date
2007-07-31
Last updated
2008-05-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypercholesterolemia

Keywords

LDL cholesterol, HDL cholesterol, natural supplement, guar gum, phytosterols, policosanol, chrysanthemum

Brief summary

This is a double-blind, placebo-controlled study to assess the effectiveness of BiosLife in lowering serum LDL cholesterol and raising HDL cholesterol. BiosLife is a natural supplement (mixed in water and taken twice daily) which contains guar gum and other natural soluble fibers, phytosterols, policosanol, and a proprietary chrysanthemum extract. Approximately 100 subjects with baseline LDL cholesterol of 110-190 mg/dL will be randomized in a 2:1 ratio to BiosLife or a look-alike placebo. Changes in lipids from baseline will be assessed at 6 weeks and 12 weeks.

Interventions

DIETARY_SUPPLEMENTBiosLife Complete
DIETARY_SUPPLEMENTPlacebo

Sponsors

Unicity International
CollaboratorUNKNOWN
University of Utah
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
Yes

Inclusion criteria

* LDL-C 110 - 190 mg/dL * For current lipid-lowering prescription therapy users, the dose of lipid-lowering medication must have been constant for 3 months with no current plan for change in dose. * Age 18 - 85 years

Exclusion criteria

* Type 1 diabetes * Severe hypertension, defined as at least 180 / 100 mmHg * Any other health condition that may interfere with the study results, as judged by the principle investigator * Allergy against any of the ingredients in the tested product * Any medical condition, in which fiber consumption is contraindicated (e.g. Crohn's disease * The use of nutritional supplements during the last two months containing one or more similar ingredients, as the tested supplement. * History of alcohol or drug abuse, psychological or other mental issues that are likely to invalidate informed consent, or limit the ability of the patient to comply with the protocol requirements * Participation in any other studies involving investigational or marketed product concomitantly or within one month prior to entry into the study * Pregnant or breast feeding * Persons who eat only 1 meal per day

Design outcomes

Primary

MeasureTime frame
HDL cholesterol12 weeks
LDL cholesterol12 weeks

Secondary

MeasureTime frame
LDL particle number12 weeks
LDL particle size distribution12 weeks
HDL particle number12 weeks
HDL particle size distribution12 weeks
VLDL particle number12 weeks
triglycerides12 weeks

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026